Histopathology and degree of hepatic fibrosis (HF) are major factors in chronic liver disease therapy and prognosis. According to certain reports, HF contributes to the development of cirrhosis, hepatocellular carcinoma, and portal venous hypertension, which in turn increases the risk of death and morbidity for patients. Liver biopsies have long been regarded as the golden standard for diagnosing HF. However, there are uncommon but serious risks associated with liver biopsies, rendering the procedure both invasive and costly. Over- or understaging of HF can also occur due to sampling mistakes and intra- or interobserver heterogeneity. Additionally, liver biopsy might not be the best way to track the development of illness due to its intrusive character. Efforts to create noninvasive techniques for HF staging that are easy, cheap, and accurate have therefore been substantial. The quest for noninvasively diagnosing and staging HF has recently led to the development of several promising novel approaches. A number of stiffness imaging techniques have been extensively studied, including those based on ultrasonography (US) and magnetic resonance (MRE) elastography, for the purpose of measuring liver stiffness (LS).